Mindray Medical International Crushes Earnings Estimates

Mindray Medical International (NYS: MR) reported earnings on May 6. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Mindray Medical International missed estimates on revenues and crushed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share grew significantly. GAAP earnings per share increased significantly.


Gross margins expanded, operating margins dropped, net margins grew.

Revenue details
Mindray Medical International tallied revenue of $242.1 million. The four analysts polled by S&P Capital IQ predicted a top line of $256.2 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $219.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.53. The four earnings estimates compiled by S&P Capital IQ predicted $0.40 per share. Non-GAAP EPS of $0.53 for Q1 were 56% higher than the prior-year quarter's $0.34 per share. GAAP EPS of $0.48 for Q1 were 55% higher than the prior-year quarter's $0.31 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 57.4%, 250 basis points better than the prior-year quarter. Operating margin was 16.1%, 70 basis points worse than the prior-year quarter. Net margin was 23.7%, 700 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $313.2 million. On the bottom line, the average EPS estimate is $0.53.

Next year's average estimate for revenue is $1.25 billion. The average EPS estimate is $2.03.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,344 members out of 1,378 rating the stock outperform, and 34 members rating it underperform. Among 258 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 246 give Mindray Medical International a green thumbs-up, and 12 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $39.53.

Is Mindray Medical International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Mindray Medical International Crushes Earnings Estimates originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »

Add a Comment

*0 / 3000 Character Maximum